Biofrontera Q2 revenue up 33% to $12.0M; net loss narrows to $0.6M

Biofrontera Inc.

Q2 net product revenue $12.0M, up 32.9% YoY; gross margin 80% vs 71% prior year.
Net loss narrowed to $0.6M ($0.05/share) from $5.3M ($0.57/share); Adjusted EBITDA $(0.2)M vs $(5.1)M.
H1 revenue $22.1M (+25.4%); operating cash use cut 76% to $1.7M; cash $4.7M at June 30.
ITC exclusion order on RhodoLED XL lamp effective July 7, 2026; remediation plan underway, full-year revenue goals unchanged.
PDUFA date late September 2026 for sBCC indication; launch expected Q1 2027 if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.